SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-009034
Filing Date
2024-02-01
Accepted
2024-02-01 16:40:01
Documents
15
Period of Report
2024-01-26
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea192600-8k_allarity.htm   iXBRL 8-K 35288
2 JAMES G. CULLEM RESIGNATION EMAIL, DATED JANUARY 27, 2024 ea192600ex17-1_allarity.htm EX-17.1 1570
  Complete submission text file 0001213900-24-009034.txt   214372

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE allr-20240126.xsd EX-101.SCH 3015
4 XBRL LABEL FILE allr-20240126_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE allr-20240126_pre.xml EX-101.PRE 22359
16 EXTRACTED XBRL INSTANCE DOCUMENT ea192600-8k_allarity_htm.xml XML 3726
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 24587530
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)